{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:17:07Z","timestamp":1762352227220},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.nucmedbio.2012.12.007","type":"journal-article","created":{"date-parts":[[2013,1,26]],"date-time":"2013-01-26T07:47:42Z","timestamp":1359186462000},"page":"424-429","source":"Crossref","is-referenced-by-count":10,"title":["Synthesis and application of a novel cysteine-based DTPA-NCS for targeted radioimmunotherapy"],"prefix":"10.1016","volume":"40","author":[{"given":"So-Young","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Don","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hak-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Ju","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.nucmedbio.2012.12.007_bb0005","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-06-2436","article-title":"Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation","volume":"13","author":"Maneesh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0010","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3121\/cmr.3.3.157","article-title":"Radioimmunotherapy for non-Hodgkin's lymphoma","volume":"3","author":"Rao","year":"2005","journal-title":"Clin Med Res"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0015","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1021\/cr9804386","article-title":"Therapeutic radiopharmaceuticals","volume":"99","author":"Volkert","year":"1999","journal-title":"Chem Rev"},{"issue":"4","key":"10.1016\/j.nucmedbio.2012.12.007_bb0020","first-page":"297","article-title":"Radioimmunotherapy of prostate cancer","volume":"48","author":"Smith-Jones","year":"2004","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"17","key":"10.1016\/j.nucmedbio.2012.12.007_bb0025","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1021\/ic0010297","article-title":"Chelators for radioimmunotherapy: I. NMR and ab initio calculation studies on 1,4,7,10-tetra(carboxyethyl)-1,4,7,10-tetraazacyclododecane (DO4Pr) and 1,4,7-tris(carboxymethyl)-10-(carboxyethyl)-1,4,7,10-tetraazacyclododecane (DO3A1Pr)","volume":"40","author":"Keire","year":"2001","journal-title":"Inorg Chem"},{"issue":"5","key":"10.1016\/j.nucmedbio.2012.12.007_bb0030","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/1097-0215(20010601)92:5<628::AID-IJC1244>3.0.CO;2-L","article-title":"[177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy","volume":"92","author":"De Jong","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0035","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1021\/cr980451q","article-title":"Radiometal-labeled agents (non-technetium) for diagnostic imaging","volume":"99","author":"Anderson","year":"1999","journal-title":"Chem Rev"},{"issue":"6","key":"10.1016\/j.nucmedbio.2012.12.007_bb0040","first-page":"967","article-title":"Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I","volume":"42","author":"Stein","year":"2001","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.nucmedbio.2012.12.007_bb0045","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.nucmedbio.2007.04.001","article-title":"Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view","volume":"34","author":"Boswell","year":"2007","journal-title":"Nucl Med Biol"},{"issue":"8","key":"10.1016\/j.nucmedbio.2012.12.007_bb0050","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S0969-8051(02)00329-3","article-title":"Holmium-166-DTPA as a liquid source for endovascular brachytherapy","volume":"29","author":"Hong","year":"2002","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0055","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/psc.427","article-title":"Synthesis of N\u03b1-Boc-N\u03b5-tetrabenzyl-DTPA-L-lysine and N\u03b1-Fmoc-N\u03b5-tetra-t-butyl-DTPA-L-lysine, building blocks for solid phase synthesis of DTPA-containing peptides","volume":"8","author":"Davies","year":"2002","journal-title":"J Peptide Sci"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0060","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.chembiol.2010.02.008","article-title":"Protein chemical modification on endogenous amino acids","volume":"17","author":"Emmauel","year":"2010","journal-title":"Chem Biol"},{"issue":"5","key":"10.1016\/j.nucmedbio.2012.12.007_bb0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1089\/cbr.2008.0493","article-title":"Preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications","volume":"23","author":"Milenic","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"10.1016\/j.nucmedbio.2012.12.007_bb0070","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.radonc.2009.04.019","article-title":"Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro","volume":"92","author":"Zhang","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0075","first-page":"1906","article-title":"(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab","volume":"46","author":"Perk","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0080","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s00259-006-0361-6","article-title":"Quantitative PET of EGFR expression in xenograft-bearing mice using (64)-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody","volume":"34","author":"Cai","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/cbr.2007.0444","article-title":"Receptor-binding, biodistribution, and metabolism studies of (64)Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors","volume":"23","author":"Li","year":"2008","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0090","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1358\/dot.2005.41.2.882662","article-title":"Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody","volume":"42","author":"Harding","year":"2005","journal-title":"Drug Today (Barc)"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0095","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.1997.15.4.1529","article-title":"Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250","volume":"15","author":"Steffens","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0100","first-page":"3268","article-title":"Phase radioimmunotherapy of metastatic renal cell carcinoma with (131)I-labeled chimeric monoclonal antibody G250","volume":"4","author":"Steffens","year":"1995","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.nucmedbio.2012.12.007_bb0105","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1021\/bc200696b","article-title":"Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of (90)Y and (177)Lu for targeted radioimmunotherapy","volume":"23","author":"Kang","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0110","first-page":"1841","article-title":"Tumor response after (90)Y-DOTA(0), Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size","volume":"42","author":"DeJong","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0115","series-title":"Anticancer drug development guide: preclinical screening, clinical trials and approval","first-page":"75","author":"Corbett","year":"1998"},{"key":"10.1016\/j.nucmedbio.2012.12.007_bb0120","series-title":"Anticancer drug development guide: preclinical screening, clinical trials and approval","first-page":"101","author":"Plowman","year":"1998"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805112003186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805112003186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T01:54:28Z","timestamp":1539914068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805112003186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0969805112003186"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2012.12.007","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}